Glucocorticoids enhance CD163 expression in placental Hofbauer cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375040 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-7170 (Electronic) Linking ISSN: 00137227 NLM ISO Abbreviation: Endocrinology Subsets: MEDLINE
    • Publication Information:
      Publication: 2017- : New York : Oxford University Press
      Original Publication: Los Angeles, Calif. : Association for the Study of Internal Secretions,
    • Subject Terms:
      Antigens, CD/*genetics ; Antigens, Differentiation, Myelomonocytic/*genetics ; Folate Receptor 2/*genetics ; Glucocorticoids/*pharmacology ; Macrophages/*metabolism ; Placenta/*cytology ; Receptors, Cell Surface/*genetics; Blotting, Western ; Dexamethasone/pharmacology ; Female ; Flow Cytometry ; Humans ; Hydrocortisone/pharmacology ; Macrophages/drug effects ; Pregnancy
    • Abstract:
      Periplacental levels of glucocorticoid (GC) peak at parturition, and synthetic GC is administered to women at risk for preterm delivery. However, little is known concerning cell-type-specific effects of GC in placenta. Hofbauer cells (HBCs) are fetal macrophages that are located adjacent to fetal capillaries in placenta. The goal of the current study was to determine whether GC treatment altered HBC gene expression and function. Western blotting and flow cytometry revealed CD163 and folate receptor-β (FR-β), markers of antiinflammatory M2 macrophages, were specifically expressed by primary cultures of HBCs immunopurified from human term placentas. GC receptor mRNA and protein levels were higher in HBCs compared with placental fibroblasts. Treatment of HBCs with cortisol or dexamethasone (DEX) markedly and specifically enhanced CD163 protein and mRNA levels, whereas expression of FR-β and CD68 were largely unresponsive to GC treatment. DEX treatment also increased hemoglobin uptake by HBCs, evidence of enhanced HBC function. The level of CD163 mRNA, but not FR-β or CD68 mRNA, was stimulated in placental explant cultures by DEX treatment, and increased CD163/FR-β and CD163/CD68 mRNA ratios sensitively reflected the response to GC. Maternal GC administration was associated with increased CD163/FR-β and CD163/CD68 mRNA ratios in placentas from women with spontaneous preterm birth. In conclusion, in vitro studies indicated that GC treatment specifically up-regulated CD163 expression in HBCs and enhanced HBC function. In addition, the observed alterations in patterns of expression of macrophage marker genes associated with maternal GC administration suggest that HBCs are in vivo targets of GC action.
    • References:
      Endocrinology. 1997 Jul;138(7):2948-52. (PMID: 9202239)
      Clin Perinatol. 2005 Sep;32(3):571-600. (PMID: 16085021)
      Horm Metab Res. 2004 Jun;36(6):423-9. (PMID: 15241735)
      Placenta. 2002 Nov;23(10):727-34. (PMID: 12398812)
      Blood. 2009 Mar 12;113(11):2578-86. (PMID: 19131549)
      Fertil Steril. 2008 Nov;90(5):1834-43. (PMID: 18166190)
      J Clin Endocrinol Metab. 1989 May;68(5):863-8. (PMID: 2715289)
      J Steroid Biochem Mol Biol. 2005 Apr;94(5):383-94. (PMID: 15876404)
      Placenta. 2007 Aug-Sep;28(8-9):841-5. (PMID: 17350092)
      Lab Invest. 2008 Oct;88(10):1057-67. (PMID: 18679377)
      Endocrinology. 2005 Nov;146(11):4619-26. (PMID: 16055431)
      Endocrinology. 2001 Jan;142(1):68-80. (PMID: 11145568)
      J Soc Gynecol Investig. 2003 Apr;10(3):136-44. (PMID: 12699875)
      JAMA. 1995 Feb 1;273(5):413-8. (PMID: 7823388)
      Am J Reprod Immunol. 2011 May;65(5):470-9. (PMID: 21087336)
      J Immunol. 1998 Aug 15;161(4):1883-90. (PMID: 9712057)
      Nature. 1985 Dec 19-1986 Jan 1;318(6047):635-41. (PMID: 2867473)
      Steroids. 1973 Apr;21(4):497-510. (PMID: 4735482)
      Can J Physiol Pharmacol. 1988 Aug;66(8):1106-12. (PMID: 2846138)
      Obstet Gynecol. 1989 Mar;73(3 Pt 1):383-9. (PMID: 2915862)
      Mol Immunol. 2010 Apr;47(7-8):1650-60. (PMID: 20299103)
      Vitam Horm. 2008;79:203-33. (PMID: 18804696)
      J Clin Endocrinol Metab. 1989 Apr;68(4):825-30. (PMID: 2537843)
      Placenta. 2010 Jun;31(6):535-44. (PMID: 20347485)
      Biol Reprod. 2004 May;70(5):1246-52. (PMID: 14681196)
      Br J Haematol. 2002 Oct;119(1):239-43. (PMID: 12358930)
      Methods Mol Biol. 2005;290:105-16. (PMID: 15361658)
      Placenta. 2005 Jul;26(6):439-48. (PMID: 15950058)
      Obstet Gynecol. 2007 Mar;109(3):739-49. (PMID: 17329528)
      Pathobiology. 1999;67(5-6):257-61. (PMID: 10725797)
      Pediatrics. 1972 Oct;50(4):515-25. (PMID: 4561295)
      J Leukoc Biol. 2000 Jan;67(1):97-103. (PMID: 10648003)
      Am J Reprod Immunol. 2010 Jun;63(6):460-71. (PMID: 20163399)
      Semin Fetal Neonatal Med. 2006 Oct;11(5):296-301. (PMID: 16621749)
      Semin Liver Dis. 2010 Aug;30(3):245-57. (PMID: 20665377)
      Lancet. 1998 Aug 29;352(9129):707-8. (PMID: 9728994)
      Obstet Gynecol. 2011 Feb;117(2 Pt 1):422-424. (PMID: 21252775)
      Endocrinology. 1993 Sep;133(3):1139-46. (PMID: 8365358)
      Biol Reprod. 2000 Apr;62(4):1075-83. (PMID: 10727280)
      Placenta. 2002 Jan;23(1):3-19. (PMID: 11869088)
      Am J Reprod Immunol. 2011 Oct;66(4):336-48. (PMID: 21545365)
      J Steroid Biochem Mol Biol. 1993 Jul;46(1):1-10. (PMID: 8338785)
      Placenta. 2011 May;32(5):380-5. (PMID: 21419483)
      Hum Pathol. 2007 Oct;38(10):1439-46. (PMID: 17889674)
      Mol Cell Endocrinol. 1989 Jan;61(1):13-21. (PMID: 2744214)
      J Immunol. 2009 Mar 15;182(6):3919-27. (PMID: 19265171)
      Acta Histochem. 2007;109(6):468-79. (PMID: 17570474)
      Cancer Res. 2009 Dec 15;69(24):9395-403. (PMID: 19951991)
      J Clin Endocrinol Metab. 1995 Jul;80(7):2203-9. (PMID: 7608280)
      Histopathology. 2008 Mar;52(4):457-64. (PMID: 18315598)
      Placenta. 2011 Nov;32(11):865-70. (PMID: 21903264)
      Am J Obstet Gynecol. 2004 Apr;190(4):878-81. (PMID: 15118606)
      Placenta. 2005 Jul;26(6):476-83. (PMID: 15950061)
      J Clin Invest. 1995 Jun;95(6):2435-41. (PMID: 7769088)
      J Mol Biol. 1972 Jun 14;67(1):99-115. (PMID: 4402888)
      Cell Tissue Res. 1980;210(2):235-47. (PMID: 7407868)
      Endocrinology. 1999 Sep;140(9):3904-8. (PMID: 10465258)
      Nature. 2001 Jan 11;409(6817):198-201. (PMID: 11196644)
      Blood. 2010 Jan 14;115(2):353-62. (PMID: 19880493)
      Am J Obstet Gynecol. 2011 Jun;204(6):520.e1-5. (PMID: 21439542)
    • Grant Information:
      R56 HD033909 United States HD NICHD NIH HHS; P01 HD054713 United States HD NICHD NIH HHS; R29 HD033909 United States HD NICHD NIH HHS; R01 HD33909-13 United States HD NICHD NIH HHS; R01 HD033909 United States HD NICHD NIH HHS
    • Accession Number:
      0 (Antigens, CD)
      0 (Antigens, Differentiation, Myelomonocytic)
      0 (CD163 antigen)
      0 (Folate Receptor 2)
      0 (Glucocorticoids)
      0 (Receptors, Cell Surface)
      7S5I7G3JQL (Dexamethasone)
      WI4X0X7BPJ (Hydrocortisone)
    • Publication Date:
      Date Created: 20121113 Date Completed: 20130222 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3529384
    • Accession Number:
      10.1210/en.2012-1575
    • Accession Number:
      23142809